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MaEndovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, mid-
and long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have
historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The
innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological
innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials
investigating the use of drug-coated stents and drug-coated balloons indicate a signiﬁcant improvement in endovascular
treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of
drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery
disease. Additionally, it provides an overview of the development of this technology, highlights landmark ongoing and
completed clinical trials, examines evidence to support the use of drug-coated technologies in combination with
other modalities, and examines promising new technological developments. Last, it summarizes the challenges and
safety concerns that have delayed U.S. Food and Drug Administration approval of these devices. (J Am Coll Cardiol Intv
2014;7:827–39) © 2014 by the American College of Cardiology Foundation.m the *Veterans Affairs North Texas Health Care System, Dallas, Texas; yUniversity of Texas Southwestern Medical Center,
llas, Texas; zUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas; and the xBrigham and Women’s
spital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts. Dr. Bhatt serves on the advisory
ards of Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; serves on the boards of directors
Boston VA Research Institute and Society of Cardiovascular Patient Care; chairs the American Heart Association Get With the
idelines Steering Committee; serves on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical
search Institute, Mayo Clinic, and Population Health Research Institute; has received honoraria from American College of
rdiology (Editor, Clinical Trials, Cardiosource), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical
search Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee),
P Communications (Editor-in-Chief, Journal of Invasive Cardiology), Population Health Research Institute (clinical trial
ering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), and WebMD (Continuing
dical Education steering committees); has received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai,
icon, Medtronic, Roche, Sanoﬁ-Aventis, and The Medicines Company; and has performed unfunded research for FlowCo,
x Pharma, and Takeda. Dr. Prasad has received speaking honoraria from AstraZeneca, Gore, and Abbott Vascular; and serves
a consultant for St. Jude Medical. Dr. Brilakis has received consulting/speaking honoraria from St. Jude Medical, Terumo,
ssen, Sanoﬁ-Aventis, Asahi, Abbott Vascular, and Boston Scientiﬁc; has received research support from Guerbet; and his
use is an employee of Medtronic. Dr. Banerjee has received research grants from Boston Scientiﬁc and The Medicines
mpany; has received consulting/speaking honoraria from Gilead, St. Jude Medical, Cordis, Boehinger Ingelheim, Sanoﬁ-
entis, and Medtronic; has ownership through his spouse of Mdcare Global; and has intellectual property in HygeiaTel. All
er authors have reported that they have no relationships relevant to the contents of this paper to disclose. Karan Sarode
d David Spelber contributed equally to this paper.
nuscript received January 30, 2014; revised manuscript received April 7, 2014, accepted May 8, 2014.
ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
BTK = below-the-knee
CLI = critical limb ischemia
DCB = drug-coated balloon(s)
DCS = drug-coated stent(s)
PAD = peripheral artery
disease
PES = paclitaxel-eluting
stent(s)
POBA = plain old balloon
angioplasty
PTA = percutaneous
transluminal angioplasty
RCT = randomized controlled
trial
SES = sirolimus-eluting
stent(s)
SFA = superﬁcial femoral
artery
TLR = target lesion
revascularization
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828W ith an increasingly aging popu-lation and a rising incidence ofdiabetes mellitus in the United
States and worldwide, the prevalence and
clinical signiﬁcance of peripheral artery dis-
ease (PAD) continues to heighten (1). Endo-
vascular intervention is a well-recognized
treatment modality for PAD, especially for
patients with multiple comorbidities, such
as coronary artery disease and chronic kid-
ney disease (2). Compared with surgical
bypass procedures, endovascular interven-
tion is associated with decreased morbidity
and a faster recovery time (3). However, the
durability of endovascular interventions for
PAD has been limited by high rates of reste-
nosis, most notably in the infrainguinal and
infrapopliteal vasculature, after percuta-
neous transluminal angioplasty (PTA) and
bare-metal stent (BMS) implantation (4).
Recently, drug-coated stents (DCS) and
drug-coated balloons (DCB) have been the
focus of technological innovation in pre-venting and treating restenosis. In the last 5 years,
6 meta-analyses have synthesized data from many
recent clinical trials to examine the efﬁcacy of DCS
and DCB compared with BMS and PTA. Overall,
the results of 5 meta-analyses, summarized in
Table 1, show superior short- and mid-term in-
creased patency and freedom from target lesion
revascularization (TLR) for DCS and DCB in the
treatment of infrapopliteal and femoropopliteal PAD
(5–10). This review provides an overview of the
development of drug-eluting technology in PAD and
highlights ongoing clinical trials and promising new
technologies.
Historically, restenosis after endovascular therapy
for PAD has been a major limitation for BMS and PTA
(11). The principal mechanism of restenosis for both
PTA and BMS is thought to be neointimal hyperplasia
due to mechanical injury of the vessel wall (12). And,
in the setting of increased biomechanical stress at the
femoropopliteal territory, BMS implantation leads to
higher rates of in-stent restenosis when used to treat
PAD versus coronary artery disease (13). The advent
of drug-eluting technology and other technologies
such as cutting balloons, atherectomy, and cryoplasty
have been a direct result of the desire to decrease
restenosis rates.
Restenosis rates are tied to anatomic distribution
of PAD, which is itself correlated with disease
severity. Critical limb ischemia (CLI), which repre-
sents 1% to 2% of PAD and is deﬁned by rest pain,
nonhealing or poorly healing ulcers, or gangrene, isthe most severe form (14). CLI is associated with long-
segment femoropopliteal lesions, multilevel disease,
and diffuse infrapopliteal lesions (15). Higher reste-
nosis rates for diffuse, infrapopliteal disease and
longer lesions have been borne out by multiple recent
studies (16,17). Fortunately, numerous clinical trials
investigating the use of DCS and DCB indicate a sig-
niﬁcant improvement with the use of these technol-
ogies in endovascular treatment outcomes in patients
with PAD.
THE DRUGS IN DRUG-DELIVERING
TECHNOLOGY
Two different drugs have been used in DCS and DCB:
paclitaxel, an antineoplastic drug; and sirolimus
(and sirolimus analogs such as zotarolimus and
everolimus), an immunosuppressant. Paclitaxel in-
hibits smooth muscle cell proliferation, extracellular
matrix secretion, and migration by enhancing the
assembly of stable but dysfunctional polymerized
microtubules. It also suppresses the release of
growth factors such as platelet-derived growth fac-
tor, providing an anti-inﬂammatory effect (4). Higher
doses of paclitaxel act at the G2/M phase and cause
mitotic arrest and cell death (18). Sirolimus also
blocks vascular smooth muscle cell migration and
proliferation by arresting the cell at the G1-S check-
point—a point in the cell cycle that does not cause
cell death (19). Both drugs are lipophilic, which en-
hances tissue uptake; however, determining and
efﬁciently delivering an optimal dose remains a
challenge. Drug densities used on DCB are generally
higher than those used on DCS because the amount
of time available for drug transfer is signiﬁcantly
less with balloon inﬂation than it is with stent
implantation (20).
DCS TECHNOLOGY
A typical DCS consists of 3 elements: a scaffold
manufactured using different kinds of metals (such as
nickel-titanium, platinum-chromium, or stainless
steel), a polymer matrix (consisting of silicone,
cellulose esters, and polyurethane), and the drug it-
self. The drug elutes at a rate proportional to degra-
dation of the polymer matrix, the latter being of
particular importance because it has been shown to
cause inﬂammatory responses and late-onset reste-
nosis. Although most ﬁrst-generation DCS used the
polymer coating to control drug elution, newer-gen-
eration stents coat the drug directly onto the outer
surface of the stent strut without using a polymer
(21). To combat the problem of thrombogenic and
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829inﬂammatory responses, a variety of bioabsorbable
materials such as polyesters, polycarbonates,
bacterial-derived polymers, and corrodible metals
have recently been incorporated into stent design
both as the polymer coating and also as the stent
scaffold itself (22).
TRIALS COMPARING DCS WITH BMS IN
FEMOROPOPLITEAL DISEASE
Studies evaluating DCS in PAD are summarized in
Table 2. Initial DCS trials in PAD tested sirolimus-
eluting stents (SES). The SIROCCO (A Clinical Inves-
tigation of the Sirolimus Coated Cordis Smart Nitinol
Self-Expandable Stent for the Treatment of Obstruc-
tive Superﬁcial Femoral Artery Disease) randomized
controlled trial (RCT), conducted in 2 phases, studied
the effectiveness of SES versus BMS in 93 patients. As
shown in Table 2, at 24-month follow-up, Duplex
ultrasound-derived in-stent restenosis and TLR rates
did not differ signiﬁcantly between patients treated
with SES and BMS. This lack of superior efﬁcacy of
SES has been attributed to 2 reasons: 1) lower than
expected restenosis rates in the BMS group, probably
due to shorter lesion lengths (mean 8.3 cm); 2) a “late
catch-up” effect, attributed, in part, to an inﬂamma-
tory response toward the degraded SES polymer
matrix (23,24).
Everolimus, a newer sirolimus analogue, shares
much of the same immunosuppressive and anti-
proliferative effects as sirolimus, but is more lipo-
philic and is more rapidly absorbed into the vessel
wall (25). The nonrandomized, single-arm trial
STRIDES (A Study to Evaluate the Safety and Per-
formance of the Dynalink-E, Everolimus Eluting
Peripheral Stent System for Treating Atherosclerotic
de Novo or Restenotic Native Superﬁcial Femoral and
Proximal Popliteal Artery Lesions) studied the effects
of everolimus-eluting stents in the superﬁcial femoral
artery (SFA) in 104 patients. Freedom from >50%
restenosis was demonstrated at 6- and 12-month
follow-up (26).
The ZILVER-PTX (Evaluation of the Zilver PTX
Drug-Eluting Peripheral Stent) RCT (n ¼ 479)
compared the efﬁcacy of paclitaxel-eluting stents
(PES) with PTA (primary randomization) and BMS
(secondary randomization) in patients with femo-
ropopliteal stenosis over 2 years. The Zilver PTX had
higher event-free survival than did PTA and BMS, and
also had higher patency rates than did the provisional
BMS group, at up to 36 months (3,27). To date, the
Zilver PTX is the only DCS to have U.S. Food and Drug
Administration approval for use during peripheral
artery interventions.
TABLE 2 DCS Trials
Trial, Year DCS Type, Sample Size
Drug, Dose,
mg/mm2
Control,
Sample Size
Arterial
Territory Primary Endpoint
Primary Outcome,
DCS vs. Control
Longest
Follow-Up
(months)
Secondary Outcomes,
DCS vs. Control
SIROCCO I and II (23),
2006
Smart (Cordis, Bridgewater,
New Jersey), 47
Sirolimus, 0.9 Smart BMS, 46 FP 6-month in-stent mean
lumen diameter stenosis
measured by
angiography and DUS
4.8% vs. 4.5% 24 24-month freedom from TLR:
93% vs. 84% (p ¼ 0.30)
24-month in-stent restenosis:
23% vs. 21%
PARADISE (30), 2010 83% Cypher (Cordis)*
17% Taxus Element (Boston
Scientiﬁc, Marlborough,
Massachusetts),* 106
Sirolimus
N/A
Paclitaxel
N/A
BASIL trial
(PTA cohort)
BTK 3-year amputation-free
survival and overall
survival
Amputation-free survival:
6% vs. 18% (p ¼ 0.04)
Overall survival: 71% vs.
63% (p ¼ 0.02)
36 12-month amputation-free
survival: 96% vs. 87%
(p ¼ 0.03)
12-month mortality:
13% vs. 18% (p ¼ 0.25)
DESTINY (29), 2011 Xience V/Prime (Abbott,
Abbott Park, Illinois),* 74
Everolimus, 2.25 Multilink Vision
BMS (Abbott), 66
BTK 12-month primary patency
measured by angiography
85% vs. 54% (p < 0.001) 12 12-month in-stent diameter
stenosis: 21% vs. 47%
(p < 0.001)
12-month freedom from TLR:
91% vs. 66% (p < 0.001)
STRIDES (26), 2011 Dynalink-E (Abbott), 104 Everolimus, 2.25 N/A FP 6 and 12-month primary
patency evaluated by DUS
6 month: 94%  2.3%
12 month: 68%  4.6%
12 12-month freedom from TLR:
80%  3.8%
ZILVER-PTX (3), 2011 Zilver PTX (Cook Medical,
Bloomgton, Indiana), 241
Paclitaxel, 3.0 PTA (primary); PTA þ
Zilver BMS
(secondary), 238
FP 12-month EFS (vs. PTA) and
PP (vs. PTA þ BMS)
measured by angiography
EFS: 90% vs. 83%
(p < 0.01)
PP: 90% vs. 73%
(p < 0.01)
36 24-month EFS: 87% vs. 78%
(p < 0.01)
24-month PP: 81% vs. 63%
(p < 0.01)
36-month freedom from TLR:
83% vs. 70%
YUKON-BTK (28), 2012 Yukon (Translumina,
Hechingen, Germany),* 82
Sirolimus,
11.7–21.9
Yukon BMS, 79 BTK 12-month EFS 66% vs. 45%
(p ¼ 0.02)
36 33-month TLR (overall):
97% vs. 88% (p ¼ 0.03)
33-month TLR (claudication):
8% vs. 25% (p ¼ 0.04)
33-month amputation (overall):
99% vs. 95% (p ¼ 0.17)
33-month amputation (CLI):
5% vs. 23% (p ¼ 0.04)
*Coronary stents.
BASIL ¼ Bypass Versus Angioplasty in Severe Ischemia of the Leg; CLI ¼ critical limb ischemia; DESTINY ¼ Prospective Randomized Multicenter Trial Comparing the Implant of a Drug Eluting Stent vs. a Bare Metal Stent in the Critically Ischemic Lower Leg; DUS ¼
duplex ultrasonography; EFS ¼ event-free survival; N/A ¼ not applicable; PARADISE ¼ Preventing Leg Amputations in Critical Limb Ischemia With Below-the-Knee Drug-Eluting Stents; PP ¼ primary patency; SIROCCO ¼ A Clinical Investigation of the Sirolimus Coated
Cordis Smart Nitinol Self-Expandable Stent for the Treatment of Obstructive Superﬁcial Femoral Artery Disease; STRIDES ¼ A Study to Evaluate the Safety and Performance of the Dynalink-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de
Novo or Restenotic Native Superﬁcial Femoral and Proximal Popliteal Artery Lesions; YUKON-BTK ¼ Yukon-Drug-Eluting Stent Below-The-Knee-Prospective Randomized Double-Blind Multicenter Study; ZILVER-PTX ¼ Evaluation of the Zilver PTX Drug-Eluting
Peripheral Stent; other abbreviations as in Table 1.
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831TRIALS COMPARING DCS WITH BMS IN
INFRAPOPLITEAL DISEASE
The YUKON-BTK (Yukon-Drug-Eluting Stent Below-
The-Knee-Prospective Randomized Double-Blind
Multicenter Study) compared SES with BMS in 161
patients with below-the knee (BTK) PAD. At 3-year
follow-up, event-free survival and freedom from
TLR was higher for the SES group. The results held for
subgroup analyses on patients with intermittent
claudication and CLI, respectively (28). The DESTINY
(Prospective Randomized Multicenter Trial Com-
paring the Implant of a Drug Eluting Stent vs. a Bare
Metal Stent in the Critically Ischemic Lower Leg) (n ¼
140) compared everolimus-eluting stents and BMS in
patients with CLI. Twelve-month follow-up showed
that everolimus-eluting stents reduced restenosis
and showed superior freedom from TLR (29).
The DESTINY and YUKON-BTK trials were
included in 2 recent meta-analyses investigating the
efﬁcacy of limus-based DCS versus BMS or PTA for the
treatment of BTK disease at 1-year follow-up (Table 1).
Antoniou et al. (8) included 4 RCTs and 2 observa-
tional studies (n ¼ 544) and demonstrated signiﬁ-
cantly higher primary patency, freedom from TLR,
and clinical improvement for patients treated with
DCS. However, no signiﬁcant differences in limb
salvage and overall survival were found (8). Fusaro
et al. (10) included 5 RCTs (n ¼ 611) and came to a
similar conclusion regarding the superior efﬁcacy of
DCS. Overall, compared with BMS or PTA, DCS ther-
apy was found to reduce the risk of reintervention
and amputation without an impact on mortality and
Rutherford class improvement (10).
The PARADISE (Preventing Leg Amputations in
Critical Limb Ischemia With Below-the-Knee Drug-
Eluting Stents) trial (30) (n ¼ 106) investigated the
use of SES in CLI and compared the results to the
BASIL (Bypass Versus Angioplasty in Severe Ischemia
of the Leg) trial. Amputation-free survival was greater
in the PARADISE trial than in the BASIL PTA group,
despite a higher prevalence of CLI patients. This dif-
ference in outcomes indicates the potential beneﬁt of
PES over PTA in the treatment of BTK lesions in CLI
patients.
Along with other SES trials, the PARADISE trial was
included in a 2013 meta-analysis (Yang et al. [9]),
which pooled outcomes for 16 combined RCTs and
non-RCTs comparing DCS, BMS, and PTA in infrapo-
pliteal disease in a total of 3,780 patients (Table 1).
The meta-analysis showed that primary BMS im-
plantation had similar restenosis and target vessel
revascularization rates as PTA did. Additionally, DCS
exhibited superior rates of 1-year primary patency,freedom from target vessel revascularization, and
limb salvage.
TRIALS WITH BIOABSORBABLE STENTS
To date, 2 published studies have investigated the use
of bioabsorbable stents in PAD. The AMS INSIGHT
(Absorbable Metal Stent Implantation for Treatment
of Below-the-Knee Critical Limb Ischemia: 6-Month
Analysis) trial (n ¼ 117) randomized patients to
absorbable stent or PTA for infrapopliteal lesions. At 6
months, angiographic patency for absorbable stents
was signiﬁcantly lower than those treated with PTA
(31.8% vs. 58%; p ¼ 0.013) (31). The GAIA (The Eval-
uation of the Biodegradable Peripheral Igaki-
Tamai Stent in the Treatment of De Novo Lesions in
the Superﬁcial Femoral Artery) trial (n ¼ 30) obser-
vational study implanted a poly-L-lactic acid biode-
gradable stent in SFA lesions, which showed a
12-month TLR rate of 57.1% and binary restenosis
rate of 67.9% (32). The ABSORB (A Clinical Evaluation
of the Everolimus Eluting Bioresorbable Vascular
Scaffold System for the Treatment of Subjects with
Critical Limb Ischemia from Occlusive Vascular
Disease of the Tibial Arteries) BTK study sought to
implement AMS in BTK vessels with the hope
of achieving similar success to coronary arteries;
however, the study has been discontinued due to
insufﬁcient enrollment (33).
DCS CONCLUSIONS
Overall, DCS improves mid-term (<2 year) outcomes in
femoropopliteal and BTK lesions, reducing restenosis
and increasing limb salvage rates. Whereas the 36-
month results of Zilver PTX are promising, additional
data from the aforementioned and forthcoming trials
are necessary to determine whether peripheral DCS
will be as impactful as they have been in coronary ar-
teries. DCS may prove to be most useful in shorter BTK
lesions (<100 mm), as smaller caliber peripheral ves-
sels may respond similarly to the coronary arteries.
Unfortunately, BTK disease and CLI are typically
associated with longer lesion length and consequently
an increase in difﬁculty and cost in treatment (9).
The question ofwhether SES or PES ismore effective
remains unanswered. Some researchers have sug-
gested that limus-based drugs may have superior
outcomes due to fewer late thrombotic complications,
as paclitaxel requires 90 days for endothelialization
comparedwith 30 days for sirolimus (19). A 2009meta-
analysis (Biondi-Zoccai et al. [7]) of 18 mostly non-
randomized trials (n ¼ 640) examined the efﬁcacy of
provisional stenting with BMS, SES, and PES in
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832patientswith BTKdisease and concluded that SESwere
superior to BMS and PES in 12-month patency (p <
0.001) and that repeat revascularization was less
commonly required after treatment with SES as
compared with PES (p ¼ 0.014). However, this meta-
analysis (7) included only 1 single-arm PES study (34),
with 29 patients treatedwith stents, and a signiﬁcantly
lower primary patency (30%) than what has been
demonstrated by other DCS in BTK trials.
DCS in PAD face many of the problems that have
been observed in DCS for coronary artery disease, such
as late thrombotic complications caused by incomplete
endothelialization of the stent (35). The optimal
duration of dual antiplatelet therapy to prevent such
complications in DCS for PAD remains controversial.
DCS have limitations in drug delivery, as the drug af-
fects only the portion of intima in contact with the
stent struts. Additionally, stenting in general could
reduce future surgical options due to lack of adequate
anastomotic bypass sites. It would be preferable to
treat lesions without placing permanent implants,
such as stents, along with possibly avoiding the
concomitant risks such as stent fracture and stent
thrombosis. This is particularly desirable in ﬂexion
points, such as the common femoral or popliteal ar-
teries. With improving endovascular technologies,
many operators increasingly prefer the option of
“leaving nothing behind” in the lesion—a strategy
bolstered by recent DCB technology.
DCB TECHNOLOGY
A DCB consists of a standard balloon catheter coated
with an antiproliferative drug and an excipient to
control the drug’s release rate. DCB therapy has
multiple potential advantages over BMS and DCS: it
avoidsmetal- or polymer-induced restenosis and stent
fracture associated with stent implantation in the
femoropopliteal arterial territory; it may distribute
antiproliferative drugs more homogenously than
stents do; and it can be used for in-stent restenosis
where avoidance of stent placement is preferred (i.e.,
tortuous vessels, bifurcation carina, and diffuse dis-
ease) (36). The current antiproliferative drug of choice
for DCB is paclitaxel due to its lipophilicity and pro-
longed tissue retention rates (20,36). Yet, interest re-
mains for the use of limus-based DCB. There are some
data to support its use and numerous ongoing clinical
trials continue to investigate limus-based DCB efﬁcacy
in preventing neointimal hyperplasia (37,38). Excipi-
ents, which enhance transfer of the drug from balloon
to tissue, vary between devices with urea, iopromide,
and polysorbate/sorbitol being among the most
commonly used (17). Ideally, the drug is released fromthe balloon and taken up by endothelial tissue after a
single inﬂation that lasts between 30 and 60 s. And,
although efﬁcient drug transfer from balloon to tissue
remains a challenge, numerous clinical trials, which
we will discuss next, are generating promising results.
TRIALS COMPARING DCBs WITH PLAIN
BALLOON ANGIOPLASTY FOR
FEMOROPOPLITEAL DISEASE
Completed studies evaluating DCB in PAD are
summarized in Table 3 and currently ongoing studies
are listed in Table 4. There is increasing evidence
supporting the superiority of DCB over PTA for the
treatment of femoropopliteal and BTK artery disease.
Four RCTs compared DCB and PTA with a primary
endpoint of 6-month late lumen loss measured by
angiography and demonstrated signiﬁcant reductions
in late lumen loss, TLR, and binary restenosis (or
increased primary patency) (39–42): the THUNDER
(Local Taxane With Short Exposure for Reduction of
Restenosis in Distal Arteries) trial (n ¼ 154); the
FemPac (Paclitaxel-Coated Versus Uncoated Balloon:
Femoral Paclitaxel Randomized Pilot Trial) (n ¼ 87);
the LEVANT I (The Lutonix Paclitaxel-Coated Balloon
for the Prevention of Femoropopliteal Restenosis)
trial (n ¼ 101); and the PACIFIER (Paclitaxel-Coated
Balloons in Femoral Indication to Defeat Restenosis)
trial (n ¼ 91). A meta-analysis of the 6-month results
of these 4 trials with a total of 381 patients concluded
that DCB therapy was associated with lower reste-
nosis rates than was PTA in the treatment of femo-
ropopliteal disease with no signiﬁcant difference in
their safety proﬁles (6) (Table 1).
The LEVANT 2 (Moxy Drug Coated Balloon vs.
Standard Balloon Angioplasty for the Treatment of
Femoropopliteal Arteries) RCT (43) (n ¼ 476) recently
released 6-month follow-up data that demonstrated
superior primary patency of DCB over PTA, with a
comparable safety proﬁle. Interestingly, the LEVANT 2
trial incorporated 2 elements into its study design in an
attempt to reduce bias: controlled pre-dilation with
standard PTA prior to randomization to limit the
number of bailout stents; and exclusion of bailout
stenting from the TLR category. Other multicenter
RCTs investigating femoropopliteal stenosis are
currently ongoing (44–48): such as the FREERIDE
(Freeway Paclitaxel Coated Balloon Catheter to Treat
Peripheral Artery Disease) trial; the ADVANCE 18PTX
(Treatment of Lesions in Superﬁcial Femoral Artery/
Popliteal ArteryWith a Paclitaxel-coated Balloon) trial;
the IN.PACT SFA II (Randomized Trial of IN.PACT Ad-
miral Drug-Eluting Balloon vs. Standard Percutaneous
Transluminal Angioplasty for the Treatment of
TABLE 3 DCB Trials
Trial, Year DCB Model/Sample Size Drug, Dose, mg/mm2 Control
Arterial
Territory Primary Endpoint
Primary Outcome,
DCB vs. PTA
Longest
Follow-Up
(months)
Secondary Outcomes,
DCB vs. Control
THUNDER (41), 2008 Paccocath (Medrad,
Warrendale,
Pennsylvania), 48
Paclitaxel-iopromide, 3.0 PTA (n ¼ 54)
and PTA þ
paclitaxel in
contrast, 52
FP 6-month LLL
measured by
angiography
0.4  1.2 vs.
1.7  1.8 vs.
2.2  1.6 mm
(all p < 0.001)
60 24-month TLR: 15% vs. 52%
(p < 0.001)
FemPac (42), 2008 PTA coated with paclitaxel
(Bavaria Medizin
Technologie, Wessling,
Germany), 45
Paclitaxel-iopromide, 3.0 PTA, 42 FP 6-month LLL
measured by
angiography
0.5  1.1 vs.
1.0  1.1 mm
(p ¼ 0.031)
24 24-month TLR: 13% vs. 50%
(p ¼ 0.001)
LEVANT I (39), 2010 Lutonix Moxy (BARD,
Murray Hill,
New Jersey), 49
Paclitaxel-polysorbate/
sorbitol, 2.0
PTA, 52 FP 6-month LLL
measured by
angiography
0.5  1.1 vs.
1.1  1.1 mm
(p ¼ 0.016)
24 24-month TLR: 30% vs. 38%
24-month MAE: 39% vs. 46%*
Schmidt et al. (17), 2011 IN.PACT Amphirion
(Medtronic, Minneapolis,
Minnesota), 104
Paclitaxel-urea, 3.0 N/A BTK 3-month binary
restenosis measured
by angiography†
27% 12 12-month TLR: 17%
12-month amputation: 4%
12-month complete wound
healing: 74%
PACIFIER (41), 2012 IN.PACT Paciﬁc
(Medtronic), 44
FreePac
Paclitaxel-urea, 3.0
PTA, 47 FP 6-month LLL
measured by
angiography
0.01  0.3 vs.
0.7  0.3 mm
(p ¼ 0.0014)
12 12-month TLR: 7% vs. 28%
(p ¼ 0.02)
Micari et al. (49), 2013 IN.PACT Admiral
(Medtronic), 105
Paclitaxel-urea, 3.0 N/A FP 12-month primary
patency measured
by DUS
84% 27 27-month TLR 14%
27-month PP: 72%
DEBATE-BTK (50), 2013 IN.PACT Amphirion
(Medtronic), 65
Paclitaxel-urea, 3.0 PTA, 67 BTK 12-month binary
restenosis measured
by angiography
and DUS
27% vs. 74%
(p < 0.001)
12 12-month TLR: 18% vs. 43%
(p ¼ 0.002)
12-month amputation:
0% vs. 2% (p ¼ 0.9)
12-month complete wound
healing: 86% vs. 67%
(p ¼ 0.01)
DEBATE-SFA (60), 2013 IN.PACT Admiral þ
BMS (Medtronic), 55
Paclitaxel-urea, 3.0 PTA þ BMS, 55 FP 12-month binary
restenosis measured
by angiography
or DUS
17% vs. 47%
(p ¼ 0.008)
12 12-month TLR: 17% vs. 33%
(p ¼ 0.07)
12-month LLL: 1.3  1.3 vs.
2.7  1.5 mm (p < 0.001)
*Deﬁned as composite of mortality, amputation, and TLR. †Derived from primary patency rates.
DEBATE-BTK ¼ Drug Eluting Balloon in peripheral intervention for Below-The-Knee Angioplasty Evaluation; DEBATE-SFA ¼ Drug Eluting Balloon in Peripheral Intervention for the Superﬁcial Femoral Artery; FemPac ¼ Paclitaxel-Coated Versus Uncoated Balloon:
Femoral Paclitaxel Randomized Pilot Trial; LEVANT I ¼ The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis; LLL ¼ late lumen loss; MAE ¼ major adverse event(s); PACIFIER ¼ Paclitaxel-Coated Balloons in Femoral Indication to
Defeat Restenosis; THUNDER ¼ Local Taxane With Short Exposure for Reduction of Restenosis in Distal Arteries; other abbreviations as in Tables 1 and 2.
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TABLE 4 Ongoing Trials With DCB
Trial Name, Patients (n) Arterial Territory DCB Model, Drug, Dose, mg/mm2 Control
Primary Outcome
(months)
LEVANT 2 (44), 476 FP Lutonix DCB Moxy, paclitaxel-
polysorbate/sorbitol, 2.0
PTA PP (12)
IN.PACT SFA II (45), 450 FP IN.PACT Admiral, paclitaxel-urea, 3.0 PTA TLR (12)
FREERIDE (46), 280 FP Freeway, paclitaxel-shellac, 3.0 PTA TLR (6)
ADVANCE 18PTX (47), 150 FP Advance 18PTX, paclitaxel, 3.0 PTA LLL (6)
ISAR-STATH (48), 150 FP Paclitaxel þ BMS, N/A PTA þ BMS or atherectomy Percentage of stenosis (6)
ILLUMENATE Pivotal (49), 350 FP Stellarex, paclitaxel, 2.0 PTA TLR (12) and PP (12)
INPACT-DEEP (51), 357 BTK IN.PACT Amphirion, paclitaxel, 3.0 PTA TLR (12)
LUTONIX BTK (53), 480 BTK Lutonix DCB Moxy, paclitaxel-
polysorbate/sorbitol, 2.0
PTA Limb salvage (12)
BAIR (56), 100 BTK ISR Legﬂow, paclitaxel-shellac þ BMS, 3.0 PTA þ BMS PP (3–12)
FAIR (57), 118 FP ISR IN.PACT, paclitaxel-urea, 3.0 PTA Binary stenosis (6)
COPA CABANA (58), 112 FP ISR Cotavance, paclitaxel-iopromide, 3.0 PTA LLL (6)
ISAR-PEBIS (59), 70 FP ISR IN.PACT, paclitaxel-urea, 3.0 PTA Percentage of stenosis (6)
FREEWAY (62), 200 FP BMS þ Freeway, paclitaxel-shellac, 3.0 BMS þ PTA TLR (6)
RAPID (63), 176 FP Legﬂow, paclitaxel-shellac þ BMS, 3.0 PTA þ BMS Binary restenosis (1–24)
DEFINITIVE AR (64), 125 FP Cotavance, paclitaxel-iopromide, 3.0 Atherectomy þ Cotavance,
paclitaxel-iopromide, 3.0
Percentage of stenosis (12)
ADCAT (65), 80 BTK IN.PACT, paclitaxel-urea, 3.0 Atherectomy þ IN.PACT,
paclitaxel-urea, 3.0
PP (6)
REAL PTX (67), 150 FP Paclitaxel, N/A Zilver PTX DCS PP (12)
IDEAS I (68), 50 BTK Paclitaxel, N/A DCS Binary restenosis (6)
ADCAT ¼ Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesion; ADVANCE 18PTX ¼ Treatment of Lesions in Superﬁcial Femoral Artery/Popliteal Artery With a
Paclitaxel-coated Balloon; BAIR ¼ Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis; COPA CABANA ¼ Cotavance Paclitaxel-Coated Balloon Versus Uncoated
Balloon Angioplasty for Treatment of In-Stent Restenosis in SFA and Popliteal Arteries; DEFINITIVE AR ¼ Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain
Vessel Patency; FAIR ¼ Femoral Artery In-Stent Restenosis; FREERIDE ¼ Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease; FREEWAY ¼ The Freeway Drug-Eluting Balloon for
Treatment of De Novo Lesions in the SFA or Popliteal Arteries; IDEAS I ¼ Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-Segment Artery Disease; ILLUMENATE Pivotal ¼
Prospective, Randomized, Single-Blind, U.S. Multicenter Study to Evaluate Treatment of Obstructive Superﬁcial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-Coated Percutaneous Angioplasty
Balloon; INPACT-DEEP ¼ Randomized Study of IN.PACT Amphirion Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia; IN.PACT SFA II ¼ Randomized Trial of
IN.PACT Admiral Drug-Eluting Balloon vs. Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superﬁcial Femoral Artery and/or Proximal Popliteal Artery;
ISAR-PEBIS ¼ Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superﬁcial Femoral Artery in Patients With Symptomatic Peripheral Artery
Disease; ISAR-STATH ¼ Efﬁcacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease; ISR ¼ in-stent restenosis; LEVANT 2 ¼Moxy Drug Coated Balloon vs. Standard
Balloon Angioplasty for the Treatment of Femoropopliteal Arteries; LUTONIX BTK ¼ Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee Arteries; RAPID ¼
Randomized Trial of Legﬂow Paclitaxel-Eluting Balloon and Stenting Versus Standard Percutaneous Transluminal Angioplasty and Stenting for the Treatment of Intermediate and Long Lesions of the
Superﬁcial Femoral Artery; REAL PTX ¼ Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery;
other abbreviations as in Tables 1 to 3.
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834Atherosclerotic Lesions in the Superﬁcial Femoral Ar-
tery and/or Proximal Popliteal Artery); the ISAR-
STATH (Efﬁcacy Study of Stenting, Paclitaxel Eluting
Balloon or Atherectomy to Treat Peripheral Artery
Disease) trial; and the ILLUMENATE Pivotal (Prospec-
tive, Randomized, Single-Blind, U.S. Multicenter
Study to Evaluate Treatment of Obstructive Superﬁcial
Femoral Artery or Popliteal Lesions with a Novel
Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Intermediate- and long-term follow-up data ex-
amining the durability of DCB therapy are also pro-
mising. At 24months, the THUNDER trial reported that
the TLR rate for patients in the DCB arm was one-half
that of the patients in the PTA arm (p < 0.001), with
results holding at the 5-year mark (p < 0.001).
Furthermore, 4% of patients in the DCB arm received
additional stents compared with 22% in the PTA arm
(40). Two-year results from the FemPac study have
also shown a durable TLR beneﬁt of DCB compared
with that of PTA (42). Micari et al. (49) conducted
another prospective multicenter study (n ¼ 105)investigating the 2-year results of DCB therapy for
femoropopliteal disease and revealed a 2-year primary
patency of 72.4% and TLR of 14.3% (p < 0.001)—pro-
visional stentingwas required in 12.3% of lesions. After
27  3 months of follow-up in 98 patients, the study
results demonstrated improvement in absolute clau-
dication distance, Rutherford classiﬁcation, and qual-
ity-of-life functional measures (p < 0.001 for all
comparisons with baseline).
TRIALS COMPARING DCB WITH PLAIN
BALLOON ANGIOPLASTY FOR
INFRAPOPLITEAL DISEASE
In 2011, Schmidt et al. (17) conducted the ﬁrst
single-arm prospective trial using DCB to treat long
infrapopliteal lesions and demonstrated superior
short- and mid-term outcomes compared with
those listed in the historical data using PTA. The
DEBATE-BTK (Drug Eluting Balloon in peripheral
intervention for Below-The-Knee Angioplasty
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835Evaluation) trial (n ¼ 132) reinforced the ﬁndings of
this trial and other smaller randomized trials with
regard to the superiority of DCB therapy versus PTA
in the setting of BTK disease in diabetic patients with
CLI. Twelve-month angiographic follow-up revealed
a signiﬁcantly lower restenosis rate for DCB versus
PTA alone, along with a striking reduction in TLR and
occlusion rate (50). However, emergent results from
the INPACT-DEEP (Randomized Study of IN.PACT
Amphirion Drug Eluting Balloon vs. Standard PTA for
the Treatment of Below the Knee Critical Limb
Ischemia) RCT (51) (n ¼ 357) showed no signiﬁcant
differences in late lumen loss or TLR, with a slight
trend toward higher amputation rates for DCB
compared with standard PTA control subjects.
Further analysis into the strikingly different out-
comes of this trial compared with those of other
contemporary DCB RCTs remains speculative due to
lack of data (52). The LUTONIX BTK (Lutonix Drug
Coated Balloon Versus Standard Balloon Angioplasty
for Treatment of Below-the-Knee Arteries) trial (53) is
an ongoing RCT with a goal of 480 patients that will
further examine the role of DCB therapy in BTK dis-
ease in patients with CLI.
DCB THERAPY FOR IN-STENT RESTENOSIS
DCB therapy has also been used for in-stent reste-
nosis of femoropopliteal arteries with some degree
of success. Stabile et al. (54,55) treated SFA in-stent
restenosis with DCB (n ¼ 39) and reported 1- and
2-year primary patency rates of 92.2% and 73.0%,
respectively. A number of ongoing RCTs are inves-
tigating DCB therapy as a strategy to tackle in-stent
restenosis (4). These studies include the BAIR
(Paclitaxel-Coated Versus Uncoated Balloon for
Treatment of Below-the-Knee In-Stent-Restenosis)
trial (56), the FAIR (Femoral Artery In-Stent Reste-
nosis) trial (57), the COPA CABANA (Cotavance
Paclitaxel-Coated Balloon Versus Uncoated Balloon
Angioplasty for Treatment of In-Stent Restenosis in
SFA and Popliteal Arteries) trial (58), and ISAR-
PEBIS (Randomized Trial of Paclitaxel Eluting
Balloon or Conventional Balloon for Treatment of
In-Stent Restenosis of the Superﬁcial Femoral Ar-
tery in Patients With Symptomatic Peripheral Artery
Disease) (59).
TRIALS EXAMINING COMBINATION
THERAPIES WITH DCBs
In light of the somewhat distinct advantages of
stent and balloon therapies, there is great interest in
therapeutic strategies that combine them. TheDEBATE SFA (Drug Eluting Balloon in Peripheral
Intervention for the Superﬁcial Femoral Artery) RCT
(60) (n ¼ 104) compared pre-dilation with DCB versus
plain old balloon angioplasty (POBA) prior to BMS
implantation. At 12-month follow-up, binary reste-
nosis rates and TLR were signiﬁcantly lowered. Data
from the DEBATE SFA trial also suggests that reduc-
tion of restenosis is maintained irrespective of lesion
length and recanalization technique.
Post-dilation strategies have also been successfully
applied to treat SFA stenosis (61). The FREEWAY
(The Freeway Drug-Eluting Balloon for Treatment
of De Novo Lesions in the SFA or Popliteal Arteries)
RCT is investigating the use of BMS plus post-
dilation with either DCB or POBA. Six-month in-
terim results for 79 patients show a TLR rate of 2.5%
for BMS þ DCB versus 10.2% for BMS þ POBA and a
higher rate of patency for DCB versus POBA (86.1%
vs. 75.7%) (62). Other ongoing RCTs such as the
RAPID (Randomized Trial of Legﬂow Paclitaxel-
Eluting Balloon and Stenting Versus Standard Per-
cutaneous Transluminal Angioplasty and Stenting
for the Treatment of Intermediate and Long Lesions
of the Superﬁcial Femoral Artery) (63) (n ¼ 176) are
investigating combination therapy with DCB and
stents for the treatment of intermediate and long
SFA lesions.
Therapeutic strategies that combine DCB as an
adjunct to plaque removal by means of directional
atherectomy or photoablation are also being in-
vestigated. The ongoing DEFINITIVE AR (Direc-
tional Atherectomy Followed by a Paclitaxel-Coated
Balloon to Inhibit Restenosis and Maintain Vessel
Patency) RCT (64) (n ¼ 102) is evaluating the efﬁcacy
of directional atherectomy followed by DCB versus
DCB therapy alone for the treatment of femo-
ropopliteal de novo stenosis. At the 30-day follow-up
assessment, atherectomy achieved higher technical
success (90% vs. 64%; p ¼ 0.004) and lowered re-
sidual diameter stenosis (18% vs. 28%; p ¼ 0.0002).
Similar ongoing RCTs such as the ADCAT (Atherec-
tomy and Drug-Coated Balloon Angioplasty in Treat-
ment of Long Infrapopliteal Lesions) trial (65) (n ¼
80) and the PHOTOPAC (Photoablative Atherectomy
Followed by a Paclitaxel-Coated Balloon to Inhibit
Restenosis in In-Stent Femoropopliteal Obstructions)
trial (66) (n ¼ 50) will continue to investigate the
long-term durability of atherectomy or photoablation
and speciﬁc clinical scenarios that warrant its
application.
There are currently no published studies that
provide direct comparisons among DCB and other
treatment alternatives such as BMS, directional
atherectomy, or DCS. An indirect comparison
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836between DCB and BMS was performed in a
meta-analysis by Fusaro et al. (5) that included 11
RCTs (n ¼ 1,464) investigating DCB versus PTA and
BMS versus PTA, the results of which were used
to compare DCB versus BMS with PTA as the common
comparator (Table 1). Although DCB and BMS per-
formed superiorly to PTA in reducing risk of TLR,
restenosis, and adverse events, the indirect com-
parison found no differences for the same endpoints
(5). Two ongoing RCTs (67,68), the REAL PTX (Ran-
domized Evaluation of the Zilver PTX Stent vs.
Paclitaxel-Eluting Balloons for Treatment of Symp-
tomatic Peripheral Artery Disease of the Femo-
ropopliteal Artery) trial (n ¼ 150) and the IDEAS-I
(Infrapopliteal Drug Eluting Angioplasty Versus
Stenting for the Treatment of Long-Segment Artery
Disease) (68) (n¼ 70), are investigating a head-to-head
comparison of DCB and DCS andwill hopefully provide
additional evidence to support a preferred endovas-
cular treatment strategy.
DCB CONCLUSIONS
Overall, there is a growing body of evidence indi-
cating signiﬁcantly lower restenosis with DCB ther-
apy using paclitaxel over PTA for de novo stenosisFIGURE 1 Freedom From TLR for DCS Compared With DCB in Femor
The drug-coated balloon (DCB) data are plotted on the red line, and the
Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomi
the Prevention of Femoropopliteal Restenosis; LEVANT 2 ¼ Moxy Drug C
Femoropopliteal Arteries; PACIFIER ¼ Paclitaxel-Coated Balloons in Fem
Short Exposure for Reduction of Restenosis in Distal Arteries; TLR ¼ tarand in-stent restenosis of the femoropopliteal and
BTK PAD. Additionally, review of all current DCS and
DCB trials for femoropopliteal PAD interventions do
not suggest an advantage of DCS over DCB (Fig. 1).
However, deﬁnitive, well-powered data are still
forthcoming, particularly with regard to long-term
clinical outcomes. The comparable efﬁcacy of DCB
versus BMS, DCS, and directional atherectomy, both
as exclusive treatment modalities and as adjunctive
therapies, also awaits data from well-designed,
ongoing, and future RCTs.
LIMITATIONS OF CURRENT DCBs AND
REGULATORY CONCERNS
Irrespective of comparable efﬁcacy, other questions
remain about the use of DCBs. The rapid, uniform,
efﬁcient, and directed transfer of the drug to the
vessel wall during balloon inﬂation with limited
downstream distribution remains the dominant
challenge (20). Success of DCB relies on the rapid
transfer of a single dose of an antiproliferative agent
into the vessel wall. Tissue delivery of the anti-
proliferative drugs from a DCB is about 8.8  3.9%
of the mean percentage of total original catheter
load (69). Table 5 depicts antiproliferative drugopopliteal Trials
drug-coated stent (DCS) data are plotted on the blue line. FemPac ¼
zed Pilot Trial; LEVANT I ¼ The Lutonix Paclitaxel-Coated Balloon for
oated Balloon vs. Standard Balloon Angioplasty for the Treatment of
oral Indication to Defeat Restenosis; THUNDER ¼ Local Taxane With
get lesion revascularization.
TABLE 5 Types of DCBs
DCBs Manufacturer Drug Carrier Drug
Dose Density,
m/mm2
Cotavance MEDRAD (Warrendale,
Pennsylvania)
Paccocath Paclitaxel 3.0
SeQuent
Please
B. Braun Melsungen AG
(Melsungen, Germany)
Paccocath Paclitaxel 3.0
IN.PACT Medtronic-Invatec
(Minneapolis, Minnesota)
FreePac Paclitaxel 3.5
Dior, Freeway Eurocor (Bonn, Germany) Shellac Paclitaxel 3.0
Moxy Lutonix-Bard (Murray Hill,
New Jersey)
Nonpolymeric Paclitaxel 2.0
Pantera Lux Biotronik (Berlin, Germany) Butyryl-tri-hexyl
citrate
Paclitaxel 3.0
AngioSculpt AngioScore (Fremont,
California)
Unknown Paclitaxel 3.0
Protege Blue Medical (Helmond,
the Netherlands)
Unknown Paclitaxel 3.0
Elutax Aachen Resonance
(Aachen, Germany)
None (2 layers of
paclitaxel)
Paclitaxel 2.0
Wombat Avidal Vascular (Halle,
Germany)
None (paclitaxel
wrapped)
Paclitaxel 3.3
Stellarex Covidien (Mansﬁeld,
Massachusetts)
Unknown
(proprietary)
Paclitaxel 2.0
Magic Touch Concept Medical (San
Jose, California)
Phospholipid-based
excipient
Sirolimus 3.3
Nanoparticle-
coated
In development* PLGA nanoparticles Paclitaxel 0.4
*Proprietary information of University of Texas Southwestern Medical Center.
DCB ¼ drug-coated balloon(s); PLGA ¼ polylactic-glycolic acid.
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837concentration on currently-available or under-
evaluation DCBs. Moreover, studies reporting
plasma levels of paclitaxel following DCB use cannot
be deemed conclusive with respect to potential sys-
temic effects of these drugs delivered to patients
during peripheral artery interventions (70). Only
z2% of total drug on the coating and z24% of the
releasable drug is transferred during 30 s of inﬂation
time (38). Approximately 98% of zotarolimus taken
up by the artery was cleared between 5 min and 24 h
after 30-s balloon inﬂation. Yet, resulting arterial
levels at 24 h reﬂect detectable and potentially ther-
apeutic levels of zotarolimus (1.4  0.5 ng/mg) (38).
Thus, a lot more work is needed to demonstrate
reliable targeted, dose-dependent biological and
vascular bed–associated clinical responses. These
concerns have been at the heart of the potential U.S.
FDA concerns regarding DCB (71).
High diffusivity and vascular wall tissue penetra-
tion of lipophilic drugs such as zotarolimus and
paclitaxel during balloon inﬂation are also associated
with near immediate clearance after balloon deﬂation
(38,72). Therefore, strategies for targeted drug de-
livery and binding could play a critical role in DCB
therapy. Pre-clinical trials using platelet-mimicking,
multiligand nanoparticles have shown enhanced
drug uptake by endothelial cells and may ultimately
decrease the drug concentration of DCB necessary to
obtain beneﬁcial outcomes (73).
An important complication associated with DCB
and PTA is acute dissection requiring a bailout stent
or, rarely, surgery. The impact of this complication
on long-term outcomes remains unclear, but it must
be considered when comparing DCB outcomes to
those of BMS or DCS trials. Two potential side effects
of DCB therapy continue to be analyzed despite the
fact that their signiﬁcance has yet to be borne out in
clinical trials: vessel wall toxicity characterized his-
tologically by excess ﬁbrin, and collagen deposition
and microparticulate embolization (36). Additionally,
an analysis of the cost-effectiveness of DCB therapy
is needed, although attempts have been made by
Dorenkamp et al. (74) and Zeller (75) provided pre-
liminary results. Optimal duration of dual antiplate-
let therapy in conjunction with DCB therapy for PAD
also remains widely debated, in contrast to the
established clinical guidelines for the use of DES in
patients with acute coronary syndrome. Some groups
have suggested dual antiplatelet therapy for 1 month,
whereas other researchers, citing pre-clinical data,
have recommended a duration of 6 months (36). The
issue of the preferred antiproliferative drug for DCB
is also important. Although pre-clinical and clinical
results have been equivocal, it is now believed thatthe availability of paclitaxel outside of intellectual
property protection and the ability to formulate
suitable carriers for paclitaxel makes it the preferred
choice for most DCBs. Further investigation of a va-
riety of DCB-related issues is clearly necessary;
however, there is no question that DCB technology
holds a great deal of promise for the treatment of
PAD.
The body of evidence demonstrating the superior
efﬁcacy of DCS and DCB compared with that of BMS
and PTA for PAD is growing. Evidence for the mid-
and long-term (>2-year) efﬁcacy of DCS in PAD
is promising, but more data from well-powered,
multicenter trials are needed. Patterns of success
for certain treatment modalities, based on anatomic
distribution and disease stage, are starting to
emerge. For femoropopliteal disease, the current
evidence suggests similar restenosis and TLR out-
comes for DCS and DCB. Treatment choice may thus
be dictated by rate of stent fracture compared with
rate of acute complications associated with balloon
angioplasty. For infrapopliteal disease, DCB may
ultimately become the treatment of choice due to
typically long lesion lengths and diffuse disease.
Two studies (DEBATE-BTK and Schmidt et al. [17])
have thus far shown promising outcomes for long
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838(>100 mm) BTK lesions treated with DCB. However,
the mean lesion lengths of most other DCB trials
have been #60 mm. These data indicate that
the number of well-powered, multicentered RCTs
remains small, and further research is needed to
compare clinical outcomes before any ﬁrm conclu-
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